TNF-α targeted therapeutic approaches in patients with hematologic malignancies

References

• Smith CA, Davis T, Anderson D et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248(4958), 1019–1023 (1990).
   PubMed Web of Science ®Google Scholar
• Loetscher H, Pan YC, Lahm HW et al. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61(2), 351–359 (1990).
   Google Scholar
• Olsson I, Lantz M, Nilsson E et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur. Haemata 42,270–275 (1989).
   PubMed Web of Science ®Google Scholar
• Schutze S, Scheurich P, Pfizenmaier K, Kronke M. Tumor necrosis factor signal transduction. Tissue-specific serine phosphorylation of a 26-kDa cytosolic protein." Bia Chem. 264,3562-3567 (1989).
   Google Scholar
• Idriss HT, Naismith JH. TNF-a and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech. 50,184–195 (2000).
   PubMed Web of Science ®Google Scholar
• Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur. Cytokine 1Vetui. 10(1), 65–70 (1999).
   Google Scholar
• Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91(1), 3–21 (1998).
   PubMed Web of Science ®Google Scholar
• Borset M, Medvedev A, Sundan A, Espevik T. The role of the two TNF receptors in proliferation, NF--KB activation and discrimination between TNF and LT a signalling in the human myeloma cell line OH-2. Cytokine 8(6), 430–438 (1996).
   Google Scholar
• Bataille R New insight in the clinical biology of multiple myeloma. Semin. Hematol. 34\(Suppl. 1), 23–28 (1997).
   Google Scholar
• Torcia M, Lucibello M, Vanier E et al. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. E. Hematol. 24,868-874 (1996).
   Google Scholar
• Shetty V, Mundle S, Alvi S et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk. Res. 20, 891–900 (1996).
   Google Scholar
• Raza A, Gezer S, Mundle S et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood86(1), 268–276 (1995).
   Google Scholar
• Gao XZ, Bi S, Copra H et al. Cytokine gene activity in AML cells in vivo in patients. Leuk. Res. 22(5), 429–438 (1998).
   PubMedGoogle Scholar
• Kurzrock R, Kantarjian H, Wetzler Metal. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage. E. Hematol. 21(1), 80–85 (1993).
   Google Scholar
• Sinha MK, Lachmann HJ, Kuriakose B, Abdulla AK, Aggarwal RK. An unusual cause of progressive heart disease. Lancet 357,1498 (2001).
   PubMedGoogle Scholar
• Drewe E, McDermott EM, Powell RJ. Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N EngZ I Med. 343(14), 1014 1045 (2000).
   Google Scholar
• Piguet PF, Grau GE, Allet B, Vassalli Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J. E. Med 166(5), 1280–1289 (1987). This was the first study to demonstrate that during acute GVHD, the activation of grafted lymphocytes leads to a local release of TNF in the cutaneous and intestinal mucosae and that the antiTNF treatment may prevent severe lesions in mice with GVHD.
   Google Scholar
• Hill GR, Cooke KR, Teshima T et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation.' Clin. Invest. 102(1), 115–123 (1998).
   Google Scholar
• Cooke KR, Hill GR, Crawford JM et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.' Clin. Invest. 102(10), 1882–1891 (1998).
   Google Scholar
• Hattori K, Hirano T, Miyajima H et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 91(11), 4051–4055 (1998).
   PubMedGoogle Scholar
• Cooke KR, Gerbitz A, Crawford JM et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.' Clin. Invest. 107(12), 1581–1589 (2001).
   Google Scholar
• Holler E, Kolb HJ, Mittennuller J et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor-a (TNF-a) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF-a (MAK 195F). Blood 86(3), 890–899 (1995)•
   Google Scholar
• Mohler KM, Torrance DS, Smith CA et al. Soluble tumor necrosis factor (TNF)receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.' Immunot 151(3), 1548–1561 (1993).
   Google Scholar
• Abraham E, Laterre PF, Garbino J et al Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter Phase III trial with 1,342 patients. Grit. Care Med. 29(3), 503–510 (2001).
   Google Scholar
• •• This double-blind, Phase III, randomized study, is a multicenter trial (in the USA, Canada and Europe) that demonstrates that Lenercept does not decrease 28-day all-cause mortality in patients with severe sepsis or early septic shock
   Google Scholar
• Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41,1552–1563 (1998).
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Vincent JL, Richard C et al CDP571, a humanized antibody to human tumor necrosis factor-a: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock CDP571 Sepsis Study Group. Grit. Care Med. 23(9), 1461–1469 (1995).
   Google Scholar
• Choy EH, Rankin EC, Kassimos D et al. The engineered human anti-tumor necrosis factor-a antibody CDP571 inhibits inflammatory pathways but not T cell activation in patients with rheumatoid arthritis.' Rheumatot 26(11), 2310–2317 (1999).
   Google Scholar
• Barrera P Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB. Effects of treatment with a fully human anti-tumour necrosis factor-a monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF-a in patients with rheumatoid arthritis. Ann. Rheum. Dis. 60(7), 660–669 (2001).
   Google Scholar
• Moreira AL, Sampaio EP, Zrnuidzinas A, Frindt R Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. j Exp. Med 177, 1675–1680 (1993).
   Google Scholar
• Gutschow M, Hecker T, Thiele A, Hauschildt S, Eger K. Aza analogues of thalidomide: synthesis and evaluation as inhibitors of tumor necrosis factor-a production in vitro. Bioorg. Med Chem. 9(4), 1059–1065 (2001).
   Google Scholar
• Han J, Thompson R Beutler B. Dexamethasone and pentmdfylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp. Med. 172(1), 391–394 (1990).
   Google Scholar
• Dezube BJ, Pardee AB, Chapman B et al. Pentmdfylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. J Acquir. Immune DOc. Syndr. 6,787–794 (1993).
   PubMed Web of Science ®Google Scholar
• Bursten S, Weeks R, West J et al. Potential role for phosphatidic acid in mediating the inflammatory responses of TNF-a and IL-113. Circ. Shock 44(1), 14–29 (1994).
   Google Scholar
• Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc. Res. Tech. 50(3), 229–235 (2000).
   Google Scholar
• Raza A, Qawi H, Lisak L et at Patients with myelodysplastic syndromes benefit from palliative therapy with arnifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 95(5), 1580–1587 (2000).
   PubMedGoogle Scholar
• Moreland LW Baumgartner SW Schiff MR et al Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N EngZ I Med 337(3), 141–147 (1997).
   Google Scholar
• ••This multicenter, randomized comparisonof etanercept with placebo in patients with refractory rheumatoid arthritis demonstrated that etanercept is safe, well-tolerated and associated with improvement in the inflammatory symptoms of rheumatoid arthritis.
   Google Scholar
• Eason JD, Pascual M, Wee S et al Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 61(2), 224–228 (1996).
   Google Scholar
• Immunex Corporation: etanercept: package insert. Seattle, WA, 2002
   Google Scholar
• Moreland LW Soluble tumor necrosis factor receptor (p75) fusion protein (etanercept) as a therapy for rheumatoid arthritis. Rheum. Dis. Clin. North Am. 24(3), 579–591 (1998).
   Google Scholar
• Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Then 21(1), 75–87; discussion 71–72 (1999).
   Google Scholar
• Bathon JM, Martin RW, Fleischmann RiVI et id A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl. J Med. 343(22), 1586–1593 (2000).
   Google Scholar
• ••This randomized study in patients withearly rheumatoid arthritis showed that etanercept is more effective and safer than methotrexate.
   Google Scholar
• Weinblatt ME, Kremer JM, Bankhurst AD et al A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl. J Med. 340(4), 253–259 (1999).
   Google Scholar
• Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl. Med. 342(11), 763–769 (2000).
   Google Scholar
• Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356(9227), 385–390 (2000).
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Waddelow T, Dong X, Albitar M, Giles FJ. Recombinant human soluble tumor necrosis factor (TNF) receptor (P75) fusion protein (TNFR:Fc)(etanercept) in patients with refractory multiple myeloma. Blood98(11), 312b (2001).
   Google Scholar
• Raza A, Dutt D, Lisak Let al. Combination of Thalidomide and etanercept for the Treatment of Patients with Myelodysplastic Syndromes (MDS). Blood 96(11), 273b — 274b (2001).
   Google Scholar
• •This study demonstrated that the combination of etanercept and thalidomide is well-tolerated and it may produce multilineage responses in a subset of patients with myelodysplastic syndromes.
   Google Scholar
• Sivaraman S, Deshpande G, Tao M et al. Effect of in vitro administration of TNF receptor fusion protein (TNFR:Fc)on the biological characteristics of A/VIL cells. Blood 96(11), 156b (2000).
   Google Scholar
• Venugopal R Mason S, Gregory A et al. In vivo administration of TNFR:Fc to acute myeloid leukemia patients: preliminary data on safety and changes in blood and bone marrow. Blood 96(11), 218b (2000).
   PubMedGoogle Scholar
• Tsimberidou AM, Thomas DA, O'Brien S et al. Recombinant human soluble tumor necrosis factor receptor (P75) fusion protein (TNFR: Fc) (etanercept) in patients with refractory hematological malignancies. Blood 98(11), 280b (2001).
   Google Scholar
• ••This pilot study demonstrated thatetanercept is safe and does not increase mortality in imrnunosuppressed patients with refractory hematologic malignancies.
   Google Scholar
• Chiang K-Y, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 73(4), 665–667 (2002).
   PubMed Web of Science ®Google Scholar
• Moreland LW Inhibitors of tumor necrosis factor for rheumatoid arthritis.' Rheumatol. 26\(Suppl. 57), 7–15 (1999).
   Google Scholar
• Skytta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin. E. Rheumatol. 18(4), 533–534 (2000).
   Google Scholar
• Spencer-Green G. Etanercept (etanercept): update on therapeutic use. Ann. Rheum. Dis. 59\(Supp1.1), 46–49 (2000).
   Google Scholar
• Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 44(5), 1149–1154 (2001).
   Google Scholar
• Bozkurt B, Torre-Anrione G, Warren MS et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (etanercept) in patients with advanced heart failure. Circulation 103(8), 1044–1047 (2001).
   PubMed Web of Science ®Google Scholar
• Deswal A, Bozkurt B, Seta Yet al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (etanercept, etanercept) in patients with advanced heart failure. Circulation 99(25), 3224–3226 (1999).
   Google Scholar
• Feldmann M, Maini RN. Anti-TNF-a therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunot 19 163–196 (2001).
   PubMed Web of Science ®Google Scholar
• Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factora receptor: Fc fusion protein. Arch. Dermata 137(7), 893–899 (2001).
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR et td Demyelination occurring during anti-tumor necrosis factor-a therapy for inflammatory arthritides. Arthritis Rheum. 44(12), 2862–2869 (2001).
   Google Scholar
• Sicotte NL, Voskuhl RR Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57(10), 1885–1888 (2001).
   PubMed Web of Science ®Google Scholar
• Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer 1 Clin. 47(1), 5–27 (1997).
   Google Scholar
• Russell E, Zeihen M, Wergin S, Litton T. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays. Arthritis Rheum. 43(4), 944 (2000).
   Google Scholar
• Werth VP, Levinson AT. Etanercept- induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. Arch. Dermatot 137(7), 953–955 (2001).
   PubMedGoogle Scholar
• Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration.' Immunot 155(10), 5038–5045 (1995).
   Google Scholar
• Fisher q, Agosti JM, Opal SM et at Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF Receptor Sepsis Medicine. N Engl. J. Med 334(26), 1697–1702 (1996). This randomized clinical trial in patients with septic shock demonstrated that etanercept does not reduce mortality, and high doses were associated with increased mortality.
   Google Scholar
• Borset M, Waage A, Brekke OL, Helseth E TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur. Haemata 53(1), 31–37 (1994).
   Google Scholar
• Hata H, Matsuzaki H, Takatsuki K. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor-a, in the myeloma cell line KHM-1A. Acta Haemata 83(3), 133–136 (1990).
   Google Scholar
• Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM. Cytokines (IL-6, TNF-a, IL-1a) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma. Cancer Detect. Prey. 20(1), 52–56 (1996).
   Google Scholar
• Gazitt Y, Shaughnessy P, Montgomery W Apoptosis-induced by TRAIL and TNF-a in human multiple myeloma cells is not blocked by BCL-2. Cytokine 11(12), 1010–1019 (1999).
   Google Scholar
• Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG. An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306, 378–380 (1983).
   Google Scholar
• Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319, 516–518 (1986).
   PubMed Web of Science ®Google Scholar
• Lichtenstein A, Berenson JR, Norman D, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74 1266–1273 (1989).
   Google Scholar
• Dune BG, Salmon SEA clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36(3), 842–854(1975).
   PubMedGoogle Scholar
• Hideshima T, Chauhan D, Shima Yet al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 962943–2950 (2000).
   Google Scholar
• Heaney ML, Golde DW. Myelodysplasia. N EngZ J. Med 340(21), 1649–1660 (1999).
   Google Scholar
• Mundle SD, Venugopal P, Cardidge JD et al. Indication of an involvement of interleukin-113 converting enzyme-like protease in intramedullary apoptotic death in the bone marrows of patients with myelodysplastic syndromes. Blood 88(7), 2640–2647 (1996).
   Google Scholar
• Cheson BD, Bennett JM, Kantarjian H et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96(12), 3671–3674 (2000).
   PubMed Web of Science ®Google Scholar
• Lilly CM, Sandhu JS, Ishizaka A et al. Pentoxyphylline prevents tumor necrosis factor-induced lung injury. Am. Rev. Respir. Dis. 139(6), 1361–1368 (1989).
   Google Scholar
• Sime PJ, Marr RA, Gauldie D et al. Transfer of tumor necrosis factor-a to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-betal and myofibroblasts. Am.j Patha 153(3), 825–832 (1998).
   PubMed Web of Science ®Google Scholar
• Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1I3 induces acute lung injury and chronic repair leading to pulmonary fibrosis." Clin. Invest. 107(12), 1529–1536 (2001).
   Google Scholar
• Warshamana GS, Corti M, Brody AR. TNF-a, PDGF, and TGF-I3(1) expression by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: TNF-a induces TGF-I3(1). Exp. MoZ PathoZ 71(1), 13–33 (2001).
   Google Scholar
• Crespo J, Cayon A, Fernandez-Gil P et id Gene expression of tumor necrosis factor-a and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34(6), 1158–1163 (2001).
   Google Scholar
• Sappino AP, Seelentag W, Peke MF, Alberto P, Vassalli P. Tumor necrosis factor/ cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients. Blood75(4), 958–962 (1990).
   PubMedGoogle Scholar
• Steensma DP, Mesa RA, Li CY, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 99(6), 2252–2254 (2002).
   PubMedGoogle Scholar
• •This clinical trial showed that etanercept is safe and improves constitutional symptoms in a subset of patients with myelofibrosis.
   Google Scholar
• Barak V, Nisman B, Polliack A. The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur. Haemata 62(2), 71–75 (1999).
   Google Scholar
• Zapata JM, Krajewska M, Krajewski S et alTNFR-associated factor family protein expression in normal tissues and lymphoid malignancies.' Immunot 165(9), 5084–5096 (2000).
   Google Scholar
• Sivaraman S, Deshpande CG, Ranganathan R et al. Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: a new role for TNFa?Microsc. Res. Tech. 50(3), 251–257 (2000).
   Google Scholar
• Ulich TR, Guo KZ, Remick D, del Castillo J, Yin SM. Endotoxin-induced cytokine gene expression in vivo. IL-6 mR.NA and serum protein expression and the in vivo hematologic effect of IL-6." Immunol. 146(7), 2316–2323 (1991).
   Google Scholar
• Henter JI, Karlen J, Calming U, Bernstrand C, Andersson U, Fadeel B. Successful treatment of Langerhans'-cell histiocytosis with etanercept. N Engl. J. Med. 345(21), 1577–1578 (2001).
   Google Scholar
• Speiser DE, Bachmann MF, Frick TW et al TNF receptor p55 controls early acute graft-versus-host disease.' Immunot 158(11), 5185–5190 (1997).
   Google Scholar
• Herve P, Flesch M, Tiberghien P et al. Phase I—II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood79(12), 3362–3368 (1992).
   PubMedGoogle Scholar
• Couriel D, Hicks K, Ipoliti C et al Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: an update. Blood 96(11), 400a (2000).
   Google Scholar
• Redei I, Knoche J, Tanner AR et al. Salvage therapy with inflhdmab for patients with severe acute and chronic GvHD. Blood 98(11), 399a (2001).
   Google Scholar
• Magalhaes-Silverman M, Lee CK, Hohl R, Becker A, Gingrich R Treatment of severe steroid refractory acute graft versus host disease with Inflhdmab. Blood 98(11), 359b (2001).
   Google Scholar
• Andolina M, Rabusin M, Maximova N, Di Leo G. Etanercept in graft-versus-host disease. Bone Marrow Transplant. 26(8), 929 (2000).
   PubMedGoogle Scholar
• Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90(8), 3204–3213 (1997).
   PubMed Web of Science ®Google Scholar
• •This study emphasized the importance of conditioning in GVHD pathophysiology and suggested that prevention of lipopolysacharide stimulation may limit the severity of GVHD after intensive conditioning for allogeneic BMT.
   Google Scholar